{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-089913","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.197932+00:00","generated_at":"2026-05-31T08:59:44.282194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Annovis Bio Q2 net loss $0.44/share; cash $12.1M; AD & PD trial data positive","bullets":["Q2 2024 net loss $0.44 per share vs $1.07 YoY; operating expenses $7.8M (R&D $5.8M, G&A $2.0M).","Cash $4.0M at June 30, 2024; increased to $12.1M as of Aug 14 via warrant exercises and ELOC.","Phase 2/3 AD study: 3.3-point ADAS-Cog11 improvement vs 0.3 placebo; effective in APOE4 carriers; no ARIA.","Phase 3 PD study: improvements in MDS-UPDRS and cognition; halted cognitive decline in all patients.","New crystalline buntanetap patent filed; FDA OK for phase 3 with crystal form; US patent for TBI; team expanded."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-089913","json":"https://secwatch.observer/filing/0001104659-24-089913.json","markdown":"https://secwatch.observer/filing/0001104659-24-089913.md","text":"https://secwatch.observer/filing/0001104659-24-089913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924089913/0001104659-24-089913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924089913/tm2421776d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:59:44.282194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}